The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(R)-2-(2-(4'-Chloro-2'-fluoro-3'-(piperidin-3-yloxy)-[1,1'-biphenyl]-3-carboxamido)-5-fluorophenyl)acetic acid ID: ALA4752851
PubChem CID: 162652581
Max Phase: Preclinical
Molecular Formula: C26H23ClF2N2O4
Molecular Weight: 500.93
Molecule Type: Unknown
Associated Items:
Names and Identifiers Canonical SMILES: O=C(O)Cc1cc(F)ccc1NC(=O)c1cccc(-c2ccc(Cl)c(O[C@@H]3CCCNC3)c2F)c1
Standard InChI: InChI=1S/C26H23ClF2N2O4/c27-21-8-7-20(24(29)25(21)35-19-5-2-10-30-14-19)15-3-1-4-16(11-15)26(34)31-22-9-6-18(28)12-17(22)13-23(32)33/h1,3-4,6-9,11-12,19,30H,2,5,10,13-14H2,(H,31,34)(H,32,33)/t19-/m1/s1
Standard InChI Key: DVMBOXLPRVXDNY-LJQANCHMSA-N
Molfile:
RDKit 2D
35 38 0 0 0 0 0 0 0 0999 V2000
9.3550 -25.6053 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.3539 -26.4248 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.0619 -26.8338 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.7716 -26.4244 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.7687 -25.6017 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.0601 -25.1964 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.0636 -27.6488 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.3542 -28.0566 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.3536 -28.8731 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.0618 -29.2826 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.7719 -28.8698 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.7690 -28.0548 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.4749 -25.1904 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.1841 -25.5964 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
11.4718 -24.3732 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
10.0626 -30.0998 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
12.8903 -25.1851 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.5980 -25.5944 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.3037 -25.1838 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.3010 -24.3658 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.5868 -23.9600 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.8840 -24.3729 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.5990 -26.4116 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.3072 -26.8193 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.3083 -27.6365 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
15.0144 -26.4098 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
11.4810 -29.2761 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
12.1873 -28.8652 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.8909 -29.2753 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.5951 -28.8678 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
13.5967 -28.0503 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.8878 -27.6419 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.1773 -28.0509 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.4756 -27.6444 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
15.0066 -23.9536 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 4 2 0
4 5 1 0
5 6 2 0
6 1 1 0
7 8 2 0
8 9 1 0
9 10 2 0
10 11 1 0
11 12 2 0
12 7 1 0
3 7 1 0
5 13 1 0
13 14 1 0
13 15 2 0
10 16 1 0
14 17 1 0
17 18 2 0
18 19 1 0
19 20 2 0
20 21 1 0
21 22 2 0
22 17 1 0
18 23 1 0
23 24 1 0
24 25 2 0
24 26 1 0
11 27 1 0
28 27 1 6
28 29 1 0
28 33 1 0
29 30 1 0
30 31 1 0
31 32 1 0
32 33 1 0
12 34 1 0
20 35 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 500.93Molecular Weight (Monoisotopic): 500.1314AlogP: 5.30#Rotatable Bonds: 7Polar Surface Area: 87.66Molecular Species: ZWITTERIONHBA: 4HBD: 3#RO5 Violations: 2HBA (Lipinski): 6HBD (Lipinski): 3#RO5 Violations (Lipinski): 2CX Acidic pKa: 3.57CX Basic pKa: 9.36CX LogP: 2.71CX LogD: 2.71Aromatic Rings: 3Heavy Atoms: 35QED Weighted: 0.41Np Likeness Score: -0.99
References 1. Velcicky J,Wilcken R,Cotesta S,Janser P,Schlapbach A,Wagner T,Piechon P,Villard F,Bouhelal R,Piller F,Harlfinger S,Stringer R,Fehlmann D,Kaupmann K,Littlewood-Evans A,Haffke M,Gommermann N. (2020) Discovery and Optimization of Novel SUCNR1 Inhibitors: Design of Zwitterionic Derivatives with a Salt Bridge for the Improvement of Oral Exposure., 63 (17): [PMID:32856916 ] [10.1021/acs.jmedchem.0c01020 ]